MX2021010668A - Proteinas de fusion de citoquinas. - Google Patents

Proteinas de fusion de citoquinas.

Info

Publication number
MX2021010668A
MX2021010668A MX2021010668A MX2021010668A MX2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A
Authority
MX
Mexico
Prior art keywords
fusion proteins
cytokine fusion
nucleic acid
acid molecules
present
Prior art date
Application number
MX2021010668A
Other languages
English (en)
Inventor
Sebastian Kreiter
Ronald Backer
Roland Kontermann
Klaus Pfizenmaier
Dafne Müller
Ugur Sahin
Friederike Gieseke
Sina Fellermeier
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2021010668A publication Critical patent/MX2021010668A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona a proteínas de fusión de citoquinas y a moléculas de ácido nucleico que codifican dichas proteínas de fusión de citoquinas. La presente invención además se relaciona a las células, organismos no humanos, composiciones farmacéuticas y kits que incluyen proteínas de fusión de citoquinas o las moléculas de ácido nucleico que las codifican, así como a su utilización como medicamentos.
MX2021010668A 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas. MX2021010668A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins

Publications (1)

Publication Number Publication Date
MX2021010668A true MX2021010668A (es) 2021-09-28

Family

ID=52394237

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009153A MX2017009153A (es) 2015-01-15 2016-01-15 Proteinas de fusion de citoquinas.
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009153A MX2017009153A (es) 2015-01-15 2016-01-15 Proteinas de fusion de citoquinas.

Country Status (11)

Country Link
US (2) US10301368B2 (es)
EP (1) EP3245223B1 (es)
JP (1) JP6813491B2 (es)
CN (2) CN107428842B (es)
AU (1) AU2016207955B2 (es)
BR (1) BR112017013956B8 (es)
CA (1) CA2971950A1 (es)
HK (2) HK1246316A1 (es)
MX (2) MX2017009153A (es)
NZ (1) NZ733266A (es)
WO (2) WO2016112983A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
IL268198B1 (en) * 2017-02-27 2024-06-01 Shattuck Labs Inc based chimeric proteins - TIGIT and LIGHT
CR20190444A (es) 2017-02-28 2019-12-17 Sanofi Sa Arn terapéutico
CA3058825A1 (en) 2017-04-06 2018-10-11 Universitat Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
CN111093689A (zh) * 2017-07-03 2020-05-01 转矩医疗股份有限公司 免疫刺激融合分子及其用途
JP2021510076A (ja) * 2018-01-10 2021-04-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞
EP3801598A1 (en) 2018-06-01 2021-04-14 Sanofi Combination therapy for treating hepatitis b virus infection
WO2020081820A1 (en) * 2018-10-17 2020-04-23 Albert Einstein College Of Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
EP4041410A4 (en) * 2019-10-08 2023-12-06 Fred Hutchinson Cancer Center GENETICALLY MODIFIED TRIMERIC CD70 PROTEINS AND THEIR USES
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US8450460B2 (en) * 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
CN103641918A (zh) * 2009-03-13 2014-03-19 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CA2868366C (en) * 2012-04-24 2017-10-03 Nordischer Maschinenbau Rud. Baader Gmbh + Co. Kg A fish corral
ES2775278T3 (es) * 2013-03-15 2020-07-24 Geoffrey W Stone Composición formada por un antígeno ligado a un ligando de la superfamilia TNF

Also Published As

Publication number Publication date
BR112017013956A8 (pt) 2019-04-02
AU2016207955A1 (en) 2017-07-20
US10808019B2 (en) 2020-10-20
EP3245223B1 (en) 2020-03-04
US20180002392A1 (en) 2018-01-04
CN113801241A (zh) 2021-12-17
JP2018503379A (ja) 2018-02-08
WO2016113395A1 (en) 2016-07-21
WO2016112983A1 (en) 2016-07-21
CN107428842B (zh) 2021-10-01
CN107428842A (zh) 2017-12-01
EP3245223A1 (en) 2017-11-22
BR112017013956B8 (pt) 2024-02-06
CA2971950A1 (en) 2016-07-21
BR112017013956B1 (pt) 2024-01-23
MX2017009153A (es) 2018-02-01
US20190276511A1 (en) 2019-09-12
JP6813491B2 (ja) 2021-01-13
HK1246316A1 (zh) 2018-09-07
NZ733266A (en) 2022-04-29
HK1246315A1 (zh) 2018-09-07
US10301368B2 (en) 2019-05-28
AU2016207955B2 (en) 2020-05-28
BR112017013956A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2021010668A (es) Proteinas de fusion de citoquinas.
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
AU2017248555B2 (en) Closed nucleic acid structures
MX2019000205A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
PH12018500252A1 (en) Factor ix fusion protiens and methods of making and using same
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
WO2016107818A8 (en) Compositions and methods for protein glycosylation
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
GB2537077A (en) Methods for sequencing nucleic acids
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2014015002A (es) Polipeptidos que tienen actividad de transgalactosilacion.
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).